Satellos Bioscience announced submission of a clinical research proposal to a Human Research Ethics Committee, or HREC, in Australia seeking regulatory authorization under their Therapeutic Goods Administration’s, or TGA’s, clinical trial notification, or CTN, scheme to conduct a first-in-human Phase 1 clinical trial of SAT-3247.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MSCLF: